NICE Backs NHS Funding for REDEMPLO in England and Wales
ARWR sits 62% above its 52-week low of $37.06 on light trading volume (0.1× avg).
Summary
NICE recommended NHS funding for REDEMPLO (plozasiran) in England and Wales, giving Arrowhead reimbursed access in its first major European market for adults with genetically confirmed FCS. The UK marketing authorisation is already in hand, so this converts approval into prescribing and revenue rather than just clearing a regulatory hurdle. It follows the August launch in Germany, the first EU market, and the company says it plans further EU rollouts in coming months. The FCS population is ultra-rare but carries high pricing potential, so UK sales alone won't move a company of this size much — the value is in proving the European reimbursement playbook works. Scotland and Northern Ireland run separate assessment paths, and those decisions plus additional EU country reimbursements are the next checkpoints for the rollout.
At the time of this announcement, ARWR was trading at $60.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.5B. The 52-week trading range was $37.06 to $95.49. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.